June 2018 Vol 9, No 6

Having a universal tool to measure patient experience, clinical outcome, and return on investment is critical to ensuring the success not only of navigation programs but oncology programs at large.
The first discussions about value-based metrics development for oncology navigation took place in November 2015 at the Academy of Oncology Nurse & Patient Navigators (AONN+) Annual Conference. Key stakeholders within the AONN+ membership identified an opportunity to develop quality outcome measures for navigation.
A maintenance regimen of lenalidomide (Revli-mid) and elotuzumab (Empliciti) after autologous stem cell transplant (ASCT) improved the quality of responses achieved with induction therapy in patients with multiple myeloma.
People from lower socioeconomic backgrounds, minority groups, and rural areas are not well represented in clinical trials and biobanking, hampering research on health disparities.

Results 1 - 5 of 5

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code